Early cholesterol-lowering drug after heart attack study
Treatments studied
Part of Heart & circulation clinical trials.
This study tests whether starting evolocumab (a cholesterol-lowering injection) soon after a heart attack helps prevent future heart problems. You'll receive the study drug or placebo for 52 weeks while your heart is monitored with imaging scans.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Had a heart attack (STEMI, NSTEMI, or unstable angina) treated with stent placement in the last week
- Age 40–75 years
- High cholesterol (LDL-C) that isn't well controlled by statins alone
- Willing to have heart imaging scans and blood tests at the start and follow-up visits
- Able to commit to 52 weeks of follow-up care and study visits
- No previous heart surgery, bypass, or prior stent placements
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether evolocumab, a monthly injection, can shrink the fatty buildup (plaque) in your heart arteries. It is for people who have early signs of heart disease or diabetes but have not had a heart attack or stroke yet.
This study tests whether a newer cholesterol-lowering injection, given early after a heart attack, helps keep the plaque in your arteries stable and reduces future risk. It compares the new medicine added to your usual statin treatment.
This study tests whether starting a cholesterol-lowering injection (a PCSK9 inhibitor) early after a heart attack can slow or shrink the buildup of plaque in other heart arteries that are not the one that was stented. If you have two other arteries with mild blockages, this treatment might help prevent future heart problems.
This trial studies whether lowering LDL (“bad cholesterol”) with a PCSK-9 inhibitor (evolocumab) improves blood flow to the heart, measured by special PET scans. It’s for people over a certain age who have stable coronary artery disease and a higher risk of heart problems.
This trial tests whether giving a powerful cholesterol-lowering drug (PCSK9 inhibitor) very early after a heart attack can help prevent further heart problems. It is for people who have had a recent heart attack and have blockages in more than one heart artery.
This study tests whether giving a strong cholesterol-lowering treatment right after a heart attack helps reduce the chance of future heart problems. It's for people who are not already on cholesterol medications.
Hear when a new Coronary artery disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.